OBJECTIVES: The purpose of this study was to evaluate the cytotoxicity of a death receptor 5 (DR5) targeting monoclonal antibody (TRA-8) in primary ovarian cancer specimens utilizing a tissue slice technique that allows for assessment of anti-tumor activity in a three-dimensional ex vivo model. METHODS: Nineteen primary ovarian tumor specimens were obtained at the time of cytoreductive surgery and tumor slices were prepared with the Krumdieck tissue slicer. Tumor slices were incubated with TRA-8 for 24 h and a dose-response curve was established for each specimen using non-linear modeling, with IC50 values used as the parameter of TRA-8 sensitivity. In parallel with ATP viability assays, TRA-8 treated and untreated tumor slices were assessed by immunohistochemistry (IHC) and western blot analysis to confirm apoptosis induction. RESULTS: Incubation with 0-1000 ng/ml TRA-8 resulted in a dose response with maximum killing observed at 1000 ng/ml compared to untreated control slices. IC50 values of 6.0 to >1000 ng/ml were calculated for individual tumor specimens. H&E, IHC, and western blot specimens demonstrated TRA-8-induced cellular death in a dose-dependent fashion via apoptosis and activation of caspases 3, 8, and 9. The apoptosis produced by varying concentrations of TRA-8 was confirmed using the TUNEL technique. Treatment with TRA-8 markedly reduced proliferation in the ovarian cancer cells as measured by expression of Ki-67/SP6. CONCLUSIONS: This study demonstrates that targeting DR5 with TRA-8 decreases cellular proliferation, increases caspase activation, and induces apoptosis in this novel three-dimensional ex vivo model of primary ovarian cancer.
OBJECTIVES: The purpose of this study was to evaluate the cytotoxicity of a death receptor 5 (DR5) targeting monoclonal antibody (TRA-8) in primary ovarian cancer specimens utilizing a tissue slice technique that allows for assessment of anti-tumor activity in a three-dimensional ex vivo model. METHODS: Nineteen primary ovarian tumor specimens were obtained at the time of cytoreductive surgery and tumor slices were prepared with the Krumdieck tissue slicer. Tumor slices were incubated with TRA-8 for 24 h and a dose-response curve was established for each specimen using non-linear modeling, with IC50 values used as the parameter of TRA-8 sensitivity. In parallel with ATP viability assays, TRA-8 treated and untreated tumor slices were assessed by immunohistochemistry (IHC) and western blot analysis to confirm apoptosis induction. RESULTS: Incubation with 0-1000 ng/ml TRA-8 resulted in a dose response with maximum killing observed at 1000 ng/ml compared to untreated control slices. IC50 values of 6.0 to >1000 ng/ml were calculated for individual tumor specimens. H&E, IHC, and western blot specimens demonstrated TRA-8-induced cellular death in a dose-dependent fashion via apoptosis and activation of caspases 3, 8, and 9. The apoptosis produced by varying concentrations of TRA-8 was confirmed using the TUNEL technique. Treatment with TRA-8 markedly reduced proliferation in the ovarian cancer cells as measured by expression of Ki-67/SP6. CONCLUSIONS: This study demonstrates that targeting DR5 with TRA-8 decreases cellular proliferation, increases caspase activation, and induces apoptosis in this novel three-dimensional ex vivo model of primary ovarian cancer.
Authors: Nichole Renae Dean; Joseph A Knowles; Emily E Helman; Joszi C Aldridge; William R Carroll; Jeffery Scott Magnuson; Lisa Clemons; Barry Ziober; Eben L Rosenthal Journal: Anticancer Drugs Date: 2010-10 Impact factor: 2.248
Authors: Elizabeth H Kerr; Peter J Frederick; Michael E Egger; Cecil R Stockard; Jeffery Sellers; Debbie DellaManna; Denise K Oelschlager; Hope M Amm; Isam-Eldin Eltoum; J Michael Straughn; Donald J Buchsbaum; William E Grizzle; Lacey R McNally Journal: Ann Surg Oncol Date: 2013-03-24 Impact factor: 5.344
Authors: Yan Liu; Oriana E Hawkins; Anna E Vilgelm; Jeffrey S Pawlikowski; Jeffrey A Ecsedy; Jeffrey A Sosman; Mark C Kelley; Ann Richmond Journal: Clin Cancer Res Date: 2015-07-07 Impact factor: 12.531
Authors: April Adams Szafran; Karri Folks; Jason Warram; Diptiman Chanda; Deli Wang; Kurt R Zinn Journal: Cancer Biol Ther Date: 2009-06 Impact factor: 4.742